Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Marina Cuchel(University of Pennsylvania), Daniel J. Rader(University of Pennsylvania), Cesare R. Sirtori(University of Milan), A. David Marais(University of Cape Town), Robert A. Hegele(Western University), Giovanni Battista Vigna(University of Ferrara), Emma A. Meagher(Translational Therapeutics (United States)), Maurizio Averna(Instituto di Biofisica), LeAnne T. Bloedon(Esperion Therapeutics (United States)), Dirk Blom(University of Cape Town), Daniel Gaudet(Brigham and Women's Hospital), Hendrik du Toit Theron(Netcare Unitas Hospital), William J. Sasiela(Inserm), Kathleen J. Propert(Translational Therapeutics (United States)), Prediman K. Shah(Cedars-Sinai Medical Center), Anna ME Du Plessis(University of Pretoria), Claudia Stefanutti(Sapienza University of Rome)
Cited by 739
Related Papers
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
|Nature Genetics|2006|2.3k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k